Malaria is a potentially fatal parasitic disease caused by Plasmodium species, transmitted by the Anopheles mosquito. It is a medical emergency — clinical deterioration or death can occur within 24–36 hours in a non-immune patient. [1-2] Approximately 2,000 cases are diagnosed annually in the US, predominantly in returning travelers. [1]
1. History
- Travel history is the single most critical HPI element — destination, dates, duration, rural vs. urban exposure, and time since return [1-2]
- Chemoprophylaxis use: agent, adherence, timing of discontinuation
- Symptom onset relative to return: P. falciparum typically presents within 4 weeks; P. vivax/ovale can present months to >1 year later [1][3]
- Symptom characterization: fever (often paroxysmal), chills/rigors, headache, myalgias, malaise, nausea/vomiting, diarrhea, abdominal pain, cough, fatigue [1][4]
- Classic cyclical fevers (q48h for P. falciparum/vivax/ovale, q72h for P. malariae) are highly variable and should not be relied upon for diagnosis [2-3]
- Important negatives: rash (uncommon), neck stiffness (suggests meningitis), hemorrhage (suggests viral hemorrhagic fever) [2]
- Prior malaria episodes, blood transfusion history, organ transplant history [3]
2. Alarm Features
- Altered mental status / impaired consciousness (GCS <11) — cerebral malaria carries ~40% case fatality [3]
- Seizures (>2 in 24 hours)
- Respiratory distress (SpO₂ <92%, RR >30, labored breathing) — suggests acidosis or pulmonary edema [4]
- Prostration (unable to sit/stand/walk)
- Shock (capillary refill ≥3 sec, SBP <80 mmHg in adults, <70 mmHg in children) [4]
- Hypoglycemia (glucose <40 mg/dL)
- Significant bleeding (hematemesis, melena, mucosal bleeding)
- Jaundice with high parasitemia
- Parasitemia ≥2% in non-immune travelers or ≥5% by any measure defines severe disease [2][4]
- Inability to tolerate oral medications [4]
3. Medications
Uncomplicated malaria (chloroquine-resistant or unknown)
- Artemether-lumefantrine (Coartem) — first-line ACT; administer with fatty food; safe in all trimesters of pregnancy [4-5]
- Atovaquone-proguanil (Malarone) — alternative; contraindicated in pregnancy and infants <5 kg [5]
- Quinine + doxycycline/tetracycline/clindamycin — 7-day regimen [5]
Uncomplicated malaria (chloroquine-sensitive)
Severe malaria
- IV artesunate — 2.4 mg/kg at 0, 12, and 24 hours, then q24h; for patients <20 kg use 3.0 mg/kg [1][4]
- Transition to oral ACT once parasitemia ≤1% and patient tolerates PO (minimum 24h IV) [4]
- If artesunate unavailable: IM artemether or IV quinine [4]
Relapse prevention (P. vivax/P. ovale)
- Primaquinetafenoquinemust check G6PD[5-6]
Medications to avoid
- Do not treat with the same agent used for prophylaxis [2]
- IV quinidine is no longer available in the US [1]
Key caution: Post-artemisinin delayed hemolysis can occur 1–3 weeks after IV artesunate (4.8% of US patients) — monitor hemoglobin, LDH, and haptoglobin for 4 weeks. [1]
The following table from the 2025 NEJM review summarizes treatment regimens:
4. Diet
- Administer artemether-lumefantrine with fatty food or milk to optimize absorption — this is clinically significant and affects drug levels [4]
- Maintain adequate hydration, especially in febrile patients
- Monitor and correct hypoglycemia aggressively (glucose <40 mg/dL defines severe malaria) — quinine and severe malaria itself both cause hypoglycemia [4]
5. Review of Systems
- Neuro: headache, confusion, altered mentation, seizures, visual changes
- GI: nausea, vomiting, diarrhea, abdominal pain (can mimic gastroenteritis)
- Pulmonary: cough, dyspnea, chest tightness (ARDS can develop, often after treatment initiation) [4]
- Heme: pallor, easy bruising, dark urine (blackwater fever)
- MSK: myalgias, arthralgias
- GU: decreased urine output (AKI)
- OB: pregnancy status — pregnant women are at increased risk for hypoglycemia, severe anemia, and placental malaria [3-4]
6. Collateral History and Family History
- Confirm travel itinerary with companions; patients may underreport rural or nighttime mosquito exposure
- Immigration history — patients from endemic regions who have been in the US may have lost partial immunity (typically within ~6 months) [1][3]
- Blood transfusion or organ transplant history (rare non-mosquito transmission)
- Heritable protective factors: sickle cell trait (HbAS) provides 85–90% protection against severe P. falciparum; G6PD deficiency may confer some protection but is critical to identify before primaquine/tafenoquine use [4]
- Duffy-negative blood type (common in sub-Saharan Africans) provides near-total protection against P. vivax [4]
7. Risk Factors
- Travel to sub-Saharan Africa (highest risk; most P. falciparum) or South/Southeast Asia, Central/South America [1]
- Non-immune travelers (no prior malaria exposure)
- Visiting friends and relatives (VFR travelers) — often do not take prophylaxis
- Non-adherence or suboptimal chemoprophylaxis
- Pregnancy (especially primigravidas) [3]
- HIV/immunosuppression — increases parasitemia and severity [4]
- Children <5 years in endemic areas
- Splenectomy or functional asplenia
- Iron-replete status (iron deficiency is paradoxically protective) [4]
8. Differential Diagnosis
9. Past Medical History
- Prior malaria episodes (species, treatment, complications)
- Splenectomy — increased risk of severe parasitemia
- Sickle cell disease/trait — protective but important for management
- G6PD status — must be known before prescribing primaquine or tafenoquine [6]
- HIV status — affects immunity and drug interactions
- Pregnancy — alters treatment selection and risk profile [4]
- Chronic kidney or liver disease — affects drug dosing and severity assessment
- Prior chemoprophylaxis regimen and adherence
10. Physical Exam
- Vitals: Fever (often >39°C, may be absent between paroxysms), tachycardia, hypotension (severe), tachypnea
- General: Diaphoresis, rigors, prostration, pallor, jaundice [8]
- HEENT: Scleral icterus, pallor of conjunctivae
- Lungs: Crackles/crepitations (pulmonary edema, ARDS); deep labored breathing (Kussmaul — acidosis) [4]
- Abdomen: Hepatomegaly, splenomegaly (tender), RUQ tenderness [8]
- Neuro: GCS assessment, meningismus (absent in malaria — if present, consider meningitis), seizure activity, abnormal posturing [4]
- Skin: Petechiae (DIC), no rash expected (rash suggests alternative diagnosis)
- Extremities: Capillary refill (≥3 sec = compensated shock), cool peripheries [4]
11. Lab Studies
- Thick and thin blood smears (Giemsa-stained) — gold standard; species identification and parasitemia quantification [2][5]
- Repeat q12–24h × 3 if initial smear negative [2]
- After treatment: repeat q12–24h to confirm declining parasitemia [1]
- Rapid diagnostic test (BinaxNOW) — results in 2–15 minutes; sensitivity 99.7% for P. falciparum at >5,000 parasites/µL; less sensitive for non-falciparum species [1]
- Must be confirmed by microscopy[9]
- CBC: Anemia, thrombocytopenia (common and helps differentiate from viral illness), leukocytosis or leukopenia [5]
- CMP: Creatinine (AKI if >3 mg/dL), glucose (hypoglycemia <40 mg/dL), bilirubin (>3 mg/dL in severe), transaminases (elevated AST/ALT) [4-5]
- Lactate: ≥5 mmol/L defines severe disease [1]
- Coagulation studies: PT/INR, fibrinogen (DIC screen)
- LDH, haptoglobin, reticulocyte count — hemolysis markers
- Blood gas: Base deficit >8 mEq/L or bicarbonate <15 mmol/L = severe acidosis [4]
- G6PD level — before prescribing primaquine/tafenoquine [6]
- Type and screen — anticipate transfusion needs
- Blood cultures — to rule out concurrent bacteremia
12. Imaging
- Chest X-ray: Indicated if respiratory symptoms, SpO₂ <92%, or suspected ARDS/pulmonary edema [4]
- CT head: If altered mental status to rule out other intracranial pathology; cerebral malaria is a clinical diagnosis
- Routine imaging is not required for uncomplicated malaria
- Abdominal ultrasound: May show hepatosplenomegaly; consider if concern for splenic rupture
13. Special Tests
- PCR (nucleic acid testing): More sensitive than microscopy; useful for species confirmation and detecting mixed infections; results not immediately available — not for initial clinical decision-making [5][9]
- Point-of-care glucose: Check immediately and serially — hypoglycemia is both a complication and a treatment side effect (quinine) [4]
- Point-of-care lactate: Rapid severity assessment
- CDC Malaria Hotline (770-488-7788, after hours 770-488-7100): Available 24/7 for diagnostic and treatment guidance [2][9]
- CDC telediagnosis service: Assists with blood smear interpretation remotely [9]
14. ECG
- Obtain ECG if using quinine (QT prolongation risk), hydroxychloroquine (QT prolongation), or mefloquine (neuropsychiatric effects) [5]
- Monitor for QTc prolongation — particularly with quinine and chloroquine
- Assess for arrhythmias in severe malaria with acidosis, electrolyte derangements, or shock
15. Assessment
Severity stratification is the most critical assessment step and determines treatment pathway:
- Uncomplicated malaria: Symptomatic parasitemia without WHO severe criteria; can tolerate oral medications [1]
- Severe malaria (any one criterion): GCS <11, seizures, parasitemia ≥5% (or ≥2% in non-immune), AKI (Cr >3 mg/dL), hypoglycemia (<40 mg/dL), ARDS, shock, severe anemia (Hgb <7 in adults), acidosis (lactate ≥5, bicarb <15), jaundice with high parasitemia, DIC, prostration, inability to take PO [2][4]
The presence of multiple complications dramatically increases mortality — from ~6% with one complication to ~43% with multiple. [4] Impaired consciousness and respiratory distress are the strongest predictors of death. [10]
16. Treatment Plan
Initial stabilization (severe malaria)
- ABCs, IV access, continuous monitoring
- IV artesunate 2.4 mg/kg at 0, 12, and 24 hours (minimum 3 doses), then q24h until PO tolerated and parasitemia ≤1% [1][4]
- Aggressive glucose monitoring and correction (D50 bolus PRN)
- IV fluids — use judiciously; avoid fluid overload (ARDS risk) [2]
- Blood transfusion for severe anemia (Hgb <5 g/dL in children, <7 g/dL in adults)
- Antipyretics (acetaminophen)
- Transition to full oral ACT course once criteria met [4]
Uncomplicated malaria
- Artemether-lumefantrine (with fatty food): 4 tablets BID × 3 days (adults) — first two doses 8 hours apart [4-5]
- OR Atovaquone-proguanil: 4 adult tablets daily × 3 days [5]
- OR Chloroquine (if chloroquine-sensitive species) [4]
Radical cure (P. vivax/P. ovale)
Consult infectious disease and contact the CDC Malaria Hotline for all confirmed cases. [2][9]
17. Disposition
Admit (ICU for severe)
- Any WHO severe malaria criteria [2]
- P. falciparum with parasitemia ≥2% in non-immune patients [4]
- Inability to tolerate oral medications
- Pregnant patients [2]
- Immunocompromised patients (HIV, asplenic) [2]
- Children and patients with no prior malarial immunity [2]
- Uncertain species identification with clinical concern
Outpatient treatment may be considered if
- Confirmed uncomplicated malaria with no severe criteria
- Able to tolerate oral medications
- Reliable follow-up ensured
- Non-P. falciparum species with low parasitemia [2]
Most patients will require admission for treatment initiation and monitoring. [8]
18. Follow Up / Return Precautions
- Post-treatment blood smears q12–24h until parasitemia clears (two consecutive negative smears) [1]
- Monitor for post-artemisinin delayed hemolysis for 4 weeks after IV artesunate — check CBC, LDH, haptoglobin at 1, 2, 3, and 4 weeks [1]
- P. vivax/P. ovale: Counsel on relapse risk if radical cure not completed; relapses can occur months later [3]
- Report all cases to the state health department [1][9]
Return precautions (patient counseling)
- Return immediately for recurrent fever, dark urine, jaundice, confusion, shortness of breath, or inability to keep medications down
- Complete the full course of antimalarials even if feeling better
- Fever after travel to an endemic area — even months later — warrants repeat evaluation [9]
- Expected recovery: uncomplicated malaria typically improves within 48–72 hours of appropriate treatment; fatigue may persist for weeks
References
1. Diagnosis, Treatment, and Prevention of Malaria in the US: A Review. — Daily JP, Minuti A, Khan N. The Journal of the American Medical Association. 2022.
2. Malaria: Prevention, Diagnosis, and Treatment. — Shahbodaghi SD, Rathjen NA. American Family Physician. 2022.
3. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents With HIV. — Constance Benson, John Brooks, Shireesha Dhanireddy, et al Infectious Diseases Society of America; Office of AIDS Research Advisory Council (2025). 2025.
4. Malaria. — Poespoprodjo JR, Douglas NM, Ansong D, Kho S, Anstey NM. Lancet. 2023.
5. Malaria. — Daily JP, Parikh S. The New England Journal of Medicine. 2025.
6. Guidelines for the Prevention and Treatment of Opportunistic Infections in Children With and Exposed to HIV. — Bill G. Kapogiannis, Franklin Yates, Wei Li, et al Office of AIDS Research Advisory Council (2025). 2025.
7. Case 4-2024: A 39-Year-Old Man with Fever and Headache after International Travel. — Ryan ET, Succi MD, Paras ML, Klontz EH. The New England Journal of Medicine. 2024.
8. Malaria: A Focused Review for the Emergency Medicine Clinician. — Long B, MacDonald A, Liang SY, et al. The American Journal of Emergency Medicine. 2024.
9. Malaria. — Alison D. Ridpath and Erika Wallender CDC Yellow Book. 2025.
10. Indicators of Life-Threatening Malaria in African Children. — Marsh K, Forster D, Waruiru C, et al. The New England Journal of Medicine. 1995.